Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cedric Hermans

Showing results (21-30 of 222) with videos related to

Pageof 23
Sort By:
Expert Opinion on Biological Therapy|December 20, 2017
Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia ASimona Raso, Cedric Hermans
Research and Practice in Thrombosis and Haemostasis|March 18, 2021
Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophiliaEvelien Krumb, Cedric Hermans
Acta Haematologica|February 22, 2023
Acquired Von Willebrand Syndrome following a SARS-CoV2 InfectionMichael Iarossi, Cedric Hermans
Expert Review of Hematology|March 11, 2020
An evaluation of the safety and efficacy of turoctocog alfa for hemophilia AAna Boban, Cedric Hermans
Blood Transfusion = Trasfusione Del Sangue|March 3, 2021
Making friends out of foes: novel therapeutic approaches for haemophiliaCatriona Mactier, Cedric Hermans
Therapeutic Advances in Hematology|September 2, 2021
Emicizumab in acquired haemophilia A: about two clinical cases and literature reviewAmandine Hansenne, Cedric Hermans
Research and Practice in Thrombosis and Haemostasis|August 11, 2021
Living with a "hemophilia-free mind" - The new ambition of hemophilia care?Evelien Krumb, Cedric Hermans
Journal of Thrombosis and Haemostasis : JTH|June 20, 2020
Safety of relaxing coagulation control by anti-tissue factor pathway inhibitor in hemophilia patients: Impact of tissue distribution of tissue factorAna Boban, Cedric Hermans
Critical Care Medicine|February 21, 2012
The complement system as another target for inhibition in septic patients: should we implement this treatment or wait for the evidence?*Olivier Lesur, Cedric Hermans
Acta Haematologica|June 10, 2009
Autosomal dominant von Willebrand disease type 2MCedric Hermans, Javier Batlle
Pageof 23

Showing results (21-30 of 222) with videos related to

Sort By:
Pageof 23
Expert Opinion on Biological Therapy|December 20, 2017
Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia ASimona Raso, Cedric Hermans
Research and Practice in Thrombosis and Haemostasis|March 18, 2021
Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophiliaEvelien Krumb, Cedric Hermans
Acta Haematologica|February 22, 2023
Acquired Von Willebrand Syndrome following a SARS-CoV2 InfectionMichael Iarossi, Cedric Hermans
Expert Review of Hematology|March 11, 2020
An evaluation of the safety and efficacy of turoctocog alfa for hemophilia AAna Boban, Cedric Hermans
Blood Transfusion = Trasfusione Del Sangue|March 3, 2021
Making friends out of foes: novel therapeutic approaches for haemophiliaCatriona Mactier, Cedric Hermans
Therapeutic Advances in Hematology|September 2, 2021
Emicizumab in acquired haemophilia A: about two clinical cases and literature reviewAmandine Hansenne, Cedric Hermans
Research and Practice in Thrombosis and Haemostasis|August 11, 2021
Living with a "hemophilia-free mind" - The new ambition of hemophilia care?Evelien Krumb, Cedric Hermans
Journal of Thrombosis and Haemostasis : JTH|June 20, 2020
Safety of relaxing coagulation control by anti-tissue factor pathway inhibitor in hemophilia patients: Impact of tissue distribution of tissue factorAna Boban, Cedric Hermans
Critical Care Medicine|February 21, 2012
The complement system as another target for inhibition in septic patients: should we implement this treatment or wait for the evidence?*Olivier Lesur, Cedric Hermans
Acta Haematologica|June 10, 2009
Autosomal dominant von Willebrand disease type 2MCedric Hermans, Javier Batlle
Pageof 23